IQP 0410

Drug Profile

IQP 0410

Alternative Names: IQP-0410; SJ-3366

Latest Information Update: 20 Aug 2009

Price : $50

At a glance

  • Originator Samjin Pharmaceutical Company
  • Developer ImQuest Life Sciences
  • Class Antiretrovirals; Pyrimidinones; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 11 Feb 2009 Antimicrobial data from a preclinical trial in HIV infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
  • 09 Feb 2009 Safety and pharmacokinetics data from preclinical trials in HIV infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009) ,
  • 07 Jan 2009 ImQuest Life Sciences files an IND application with the US FDA for HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top